LANSOPRAZOLE CAPSULE (DELAYED RELEASE)

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

LANSOPRAZOLE

Доступна с:

PHARMASCIENCE INC

код АТС:

A02BC03

ИНН (Международная Имя):

LANSOPRAZOLE

дозировка:

30MG

Фармацевтическая форма:

CAPSULE (DELAYED RELEASE)

состав:

LANSOPRAZOLE 30MG

Администрация маршрут:

ORAL

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

PROTON-PUMP INHIBITORS

Обзор продуктов:

Active ingredient group (AIG) number: 0127666001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2014-11-21

Характеристики продукта

_LANSOPRAZOLE _
_Page 1 of 83_
PRODUCT MONOGRAPH
PR LANSOPRAZOLE
Lansoprazole Delayed-Release Capsules, USP
15 mg and 30 mg
H
+
, K
+
– ATPase Inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
Submission Control No: 258396
Date of Revision:
November 19, 2021
_LANSOPRAZOLE _
_Page 2 of 83_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................................
5
WARNINGS
AND
PRECAUTIONS
.......................................................................................................................
5
ADVERSE
REACTIONS
.......................................................................................................................................
11
DRUG
INTERACTIONS
.......................................................................................................................................
21
DOSAGE
AND
ADMINISTRATION....................................................................................................................
23
OVERDOSAGE
.....................................................................................................................................................
26
ACTION
AND
CLINICAL
PHARMACOLOGY
..................................................................................................
26
STORAGE
AND
STABILITY
...............................................................................................................................
31
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
....